Highest-materiality recent filing
iMDx reports Q2 net loss of $11.3M; FDA issues Additional Information Request for GraftAssureDx
Q2 2026 revenue ~$239K; gross profit $157K (65.7% margin); net loss $11.3M ($0.31/share); adjusted net loss $8.3M ($0.23/share).
iMDx reports Q1 net loss $4.3M; signs first GALACTIC trial site, advances FDA submission
Q1 revenue ~$32K, gross profit $15K; net loss $4.3M ($0.12/share); non-GAAP net loss $9.6M ($0.28/share).
iMDx signs specimen collection agreement with Quest for GraftAssureCore test
Entered Specimen Collection Agreement with Quest Diagnostics for services supporting GraftAssureCoreTM test.
iMDx submits GraftAssureDx to FDA; Q4 revenue $1.1M, net loss $23.0M
Submitted GraftAssureDx kidney transplant test to FDA on March 25; expects 150-day review and authorization this year.
IMDX raises $26M in registered direct offering; funds heart transplant rejection test development
Gross proceeds ~$26M from 4,525,976 shares/pre-funded warrants at $5.75/unit; net proceeds ~$24.5M.
IMDX Q2 rev $518K, net loss $9.7M; FDA on track for GraftAssureDx submission by year-end
Revenue $518K vs $104K YoY; gross margin 67.6%, up from 62% in Q1.
Oncocyte renames to Insight Molecular Diagnostics (iMDx), ticker changes to IMDX on June 18
Company changed name from Oncocyte Corp to Insight Molecular Diagnostics Inc. effective June 13, 2025.
Oncocyte Q1 revenue $2.14M, gross margin 62%; transplant trial gets IRB approval
Q1 2025 pharma services revenue $2.14M with 62% gross margin, up from 40% in Q4 2024.
Oncocyte Q4 revenue $1.5M, GAAP loss $33.5M; transplant test on track for 2026 FDA authorization
Q4 2024 pharma-services revenue $1.5M; full-year $1.9M; gross margin 40%.
Oncocyte raises $29.1M equity; Bio-Rad invests; funds transplant assay to FDA clearance
Gross proceeds of $29.1M from registered direct ($7.4M) and PIPE ($21.7M) offerings at $2.05/share.
Oncocyte reports Q3 loss of $13.5M; GraftAssure signed 2% US, 9% German transplant volumes
Q3 revenue $115K from pharma services; loss from operations $13.5M ($0.98/sh); non-GAAP loss $5.6M.
Oncocyte raises $10.2M in private placement, adds two major transplant centers as customers
Private placement of 3.46M shares at $2.948/share raises ~$10.2M gross; includes participation from strategic partner Bio-Rad.
Oncocyte reports Q2 revenue $104K, loss $0.36/sh; launches GraftAssure at two centers
Revenue of $104K from pharma services; operating expenses $4.7M; loss from ops $4.5M ($0.36/sh).
Oncocyte appoints Andrea James as CFO, effective June 17, 2024
Andrea James appointed CFO; previously Chief Communications Officer at Axon Enterprise (AXON) and IR roles at Tesla.
Oncocyte Q1 revenue down 41% to $176K; operating loss $9.3M; Bio-Rad partnership
Net revenue $176K, down 41% YoY; operating loss $9.3M (incl. $3.3M contingent consideration loss) vs income $5.9M in Q1 2023.
Oncocyte raises $15.8M in private placement; FY2023 revenue $1.5M, ops loss $25.1M
Private placement of 5.1M shares + pre-funded warrants for 342k shares at $2.92/share; gross proceeds ~$15.8M.
Oncocyte partners with Bio-Rad for global transplant assay; Bio-Rad makes equity investment
10-year collaboration to develop/commercialize GraftAssure RUO and VitaGraft IVD assays on Bio-Rad's ddPCR platform.
Oncocyte launches VitaGraft Kidney test for transplant monitoring
VitaGraft Kidney, a blood-based dd-cfDNA test for kidney transplant rejection, is now broadly available upon request.
Oncocyte Q3 rev $0.4M, op loss $6.5M; VitaGraft Kidney gets CMS coverage
Revenue $0.4M; net operating loss $6.5M vs $1.7M in Q3 2022 (which included $6.1M fair value benefit).
Oncocyte's VitaGraft Kidney test receives Medicare coverage decision from Palmetto GBA
Palmetto GBA, a Medicare Administrative Contractor, issued final LCD for VitaGraft Kidney test.
Oncocyte Q2 revenue $0.5M, net operating loss $8.3M; appoints James Liu interim CFO
Revenue $0.5M, cost of revenue $0.2M; net operating loss $8.3M vs $8.6M YoY, down $0.3M.
Oncocyte implements 1-for-20 reverse stock split to regain Nasdaq compliance
Reverse stock split at 1-for-20 effective 5:00 p.m. PT July 24, 2023; trading on split-adjusted basis July 25.
Oncocyte Q1 revenue down 50% to $0.7M; CFO Anish John to leave June 15
Revenue $0.7M, down 50% YoY; net operating income $2.9M vs loss of $9.4M.
Oncocyte cuts ~20% of workforce; expects $0.3M severance charges in Q2 2023
Reduction in force involving approximately 20% of employees, announced April 12, 2023.
Oncocyte raises ~$13.5M in offering of 45.5M shares at $0.302-$0.354
Net proceeds of ~$13.5M after $250K advisory fee and other expenses.
Oncocyte reports 2022 net loss of $72.9M; revenue down 27%; sells DetermaRx, cuts workforce
Net loss for 2022 was $72.9M vs $64.1M in 2021; accumulated deficit $260.7M.
On March 4, 2025, the Company promoted James Liu to Vice President Accounting, Controller, Treasurer and Principal Accounting Officer, effective March 10, 2025.
On June 17, 2024, the Board of Directors (the “Board”) of Oncocyte Corporation (the “Company”) appointed Andrea James to serve as the Company’s Chief Financial Officer, effective June 17, 2024.
On that same date, the Company appointed Mr. Liu to the additional role of interim Principal Financial Officer.
On August 4, 2023, the Company promoted James Liu to Senior Director, Controller & Principal Accounting Officer.
On March 2, 2023, Oncocyte Corporation (the “Company”) issued a press release announcing that Joshua Riggs, the Interim Chief Executive Officer of the Company, was appointed the Chief Executive Officer of the Company, effective February 24, 2023
On May 11, 2023, Oncocyte announced that Anish John, our Chief Financial Officer, will be leaving the Company on June 15, 2023.
Effective February 24, 2023, the Board of Directors of Oncocyte Corporation (“Oncocyte” or the “Company”) appointed Joshua Riggs as Chief Executive Officer of the Company.
Mr. Riggs has also been appointed President and joined the Company’s Board of Directors effective February 28, 2023.
Mr. Riggs has also been appointed President and joined the Company’s Board of Directors effective February 28, 2023.
the positions occupied by Gisela Paulsen, President and Chief Operating Officer, and Douglas Ross, Chief Scientific Officer, will be eliminated.
the positions occupied by Gisela Paulsen, President and Chief Operating Officer, and Douglas Ross, Chief Scientific Officer, will be eliminated.
On November 30, 2022, Oncocyte Corporation (the “Company”) issued a press release announcing that Ronald Andrews will step down from his role as President and Chief Executive Officer and director of the Board of Directors of the Company (the “Board”), effective as of December 1, 2022
Max materiality 0.85 · Median 0.60 · Most common event other_material